KalVista Pharmaceuticals Inc [KALV] stock prices are up 3.92% to $15.91 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KALV shares have gain 6.49% over the last week, with a monthly amount glided 6.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
KalVista Pharmaceuticals Inc [NASDAQ: KALV] stock has seen the most recent analyst activity on January 09, 2026, when Needham reiterated its Buy rating and also boosted its price target to $35 from $32. Previously, Needham reaffirmed its Buy rating on January 06, 2026, and elevated its price target to $32. On January 31, 2025, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $19 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $30 on January 07, 2025. BofA Securities initiated its recommendation with a Buy and recommended $22 as its price target on December 18, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on June 15, 2020, and assigned it a price target of $30. In a note dated July 29, 2019, SVB Leerink initiated an Outperform rating and provided a target price of $31 on this stock.
The stock price of KalVista Pharmaceuticals Inc [KALV] has been fluctuating between $8.25 and $19.00 over the past year. Currently, Wall Street analysts expect the stock to reach $32.33 within the next 12 months. KalVista Pharmaceuticals Inc [NASDAQ: KALV] shares were valued at $15.91 at the most recent close of the market. An investor can expect a potential return of 103.21% based on the average KALV price forecast.
Analyzing the KALV fundamentals
Gross Profit Margin for this corporation currently stands at -0.17% with Operating Profit Margin at -13.43%, Pretax Profit Margin comes in at -13.4%, and Net Profit Margin reading is -13.91%. To continue investigating profitability, this company’s Return on Assets is posted at -0.62, Equity is -2.82 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 8.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that KalVista Pharmaceuticals Inc [NASDAQ:KALV]’s Current Ratio is 7.22. Also, the Quick Ratio is 7.21, while the Cash Ratio stands at 5.4. Considering the valuation of this stock, the price to sales ratio is 562.37, the price to book ratio is 47.30.
Transactions by insiders
Recent insider trading involved Palleiko Benjamin L, CHIEF EXECUTIVE OFFICER, that happened on Dec 08 ’25 when 7294.0 shares were sold. Chief Commercial Officer, Sweeny Nicole completed a deal on Nov 24 ’25 to sell 3813.0 shares. Meanwhile, Chief Financial Officer Piekos Brian sold 4471.0 shares on Nov 24 ’25.
